Vutrisiran
ALN-TTRSC02-003
Phase 3 small_molecule active
Quick answer
Vutrisiran for Transthyretin Amyloidosis (ATTR) With Cardiomyopathy is a Phase 3 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- ALNYLAM PHARMACEUTICALS, INC.
- Indication
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active